跳至主要内容
临床试验/NCT02334345
NCT02334345已完成不适用

Skin Protection During Radiotherapy in Patients With Breast Cancer: A Comparative Study of Evoskin® Verus Trixéra®

University Hospital, Limoges1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
25
试验地点
1
主要终点
Average of the radiation dermatitis intensity

研究概览

简要总结

Radiotherapy may cause severe skin changes that significantly interfere with the patient's quality of life and may reduce radiotherapy effectiveness. Many skin care instructions and various topical agents are recommended to help patients in the management of radiation skin reactions, but evidence to support the value of the topical treatments of the irradiated skin is lacking. In the present study we investigated the effects of two topical agents used as supportive care to protect skin during radiotherapy.

详细描述

Women with breast cancer and were to receive breast radiotherapy to 50 Gy were enrolled in a prospective randomized trial to compare the effectiveness of Evoskin®) for protecting skin compared to Trixiera. To account for individual differences in radiation each subject served as her own control, as each was to apply the experimental and control agents to the irradiated breast. Each patient was randomly assigned to use Evoskin on the half of the irradiated breast and to use the Triexiera on the other half. Dermatitis was graded weekly by means of a spectrophotometer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 18 years old or more
  • Patients with breast cancer for which a treatment by radiotherapy is planned
  • No concomitant chemotherapy
  • Signed informed consent

排除标准

  • Cutaneous neoplasia radiotherapy
  • Total mastectomy
  • Bilateral breast cancer
  • Dark skinDiseases enhancing radiosensitivity Patient with a generalized skin disorder
  • Pregnant, breast-feeding woman

研究组 & 干预措施

EVOSKIN

Experimental

Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.

干预措施: Evoskin (Drug)

TRIXIERA

Active Comparator

Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.

干预措施: Trixiera (Drug)

结局指标

主要结局

Average of the radiation dermatitis intensity

时间窗: at 3 months

Radiation dermatitis will be assessed by means of a spectrophotometer after the patient has received 50Gy

次要结局

  • Clinical grade of dermatitis(at 3 months)

研究者

发起方
University Hospital, Limoges
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验